TCM Biotech International Corp.
TCM Biotech International Corp., a biotech company, engages in the research and development of drugs for liver diseases. The company offers medical devices, such as therapy for osteoarthritis, intra-articular implant of hyaluronic acid, automated blood cell separator, absorbable adhesion barrier material, prosthetic and orthotic accessory, and pellefeel mask pressure relief pad; and pharmaceutica… Read more
TCM Biotech International Corp. (4169) - Total Assets
Latest total assets as of September 2025: NT$1.18 Billion TWD
Based on the latest financial reports, TCM Biotech International Corp. (4169) holds total assets worth NT$1.18 Billion TWD as of September 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
TCM Biotech International Corp. - Total Assets Trend (2019–2024)
This chart illustrates how TCM Biotech International Corp.’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
TCM Biotech International Corp. - Asset Composition Analysis
Current Asset Composition (December 2024)
TCM Biotech International Corp.'s total assets of NT$1.18 Billion consist of 68.7% current assets and 31.3% non-current assets.
| Asset Category | Amount (TWD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | NT$0.00 | 19.7% |
| Accounts Receivable | NT$141.65 Million | 12.0% |
| Inventory | NT$128.93 Million | 10.9% |
| Property, Plant & Equipment | NT$0.00 | 0.0% |
| Intangible Assets | NT$20.72 Million | 1.8% |
| Goodwill | NT$0.00 | 0.0% |
Asset Composition Trend (2019–2024)
This chart illustrates how TCM Biotech International Corp.'s asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: TCM Biotech International Corp.'s current assets represent 68.7% of total assets in 2024, an increase from 15.8% in 2019.
- Cash Position: Cash and equivalents constituted 19.7% of total assets in 2024, up from 15.8% in 2019.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 1.0% of total assets, an increase from 0.0% in 2019.
- Asset Diversification: The largest asset category is accounts receivable at 12.0% of total assets.
TCM Biotech International Corp. Competitors by Total Assets
Key competitors of TCM Biotech International Corp. based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
MedPacto Inc
KQ:235980
|
Korea | ₩51.58 Billion |
|
2H0
F:2H0
|
Germany | €15.27 Million |
|
Shenzhen CAU Technology Co Ltd
SHE:000004
|
China | CN¥260.55 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.58 Billion |
|
Nanhua Bio Medicine Co Ltd
SHE:000504
|
China | CN¥841.96 Million |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
|
China | CN¥509.14 Million |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
|
Hualan Biological EngineeringInc
SHE:002007
|
China | CN¥16.27 Billion |
TCM Biotech International Corp. - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Moderate asset utilization - TCM Biotech International Corp. generates 0.56x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Moderate ROA - For every $100 in assets, TCM Biotech International Corp. generates $ 1.78 in net profit.
TCM Biotech International Corp. - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 10.03 | 4.95 | 0.97 |
| Quick Ratio | 8.43 | 4.03 | -0.62 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | NT$742.52 Million | NT$ 782.77 Million | NT$ -4.02 Million |
TCM Biotech International Corp. - Advanced Valuation Insights
This section examines the relationship between TCM Biotech International Corp.'s asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 12.61 |
| Latest Market Cap to Assets Ratio | 0.21 |
| Asset Growth Rate (YoY) | -10.6% |
| Total Assets | NT$1.18 Billion |
| Market Capitalization | $253.04 Million USD |
Valuation Analysis
Below Book Valuation: The market values TCM Biotech International Corp.'s assets below their book value (0.21 x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: TCM Biotech International Corp.'s assets decreased by 10.6% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for TCM Biotech International Corp. (2019–2024)
The table below shows the annual total assets of TCM Biotech International Corp. from 2019 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | NT$1.18 Billion | -10.63% |
| 2023-12-31 | NT$1.32 Billion | +53.32% |
| 2022-12-31 | NT$862.87 Million | +5.22% |
| 2021-12-31 | NT$820.06 Million | +6.19% |
| 2020-12-31 | NT$772.26 Million | +0.95% |
| 2019-12-31 | NT$764.96 Million | -- |